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ABSTRACT
Methicillin-resistant Staphylococcus aureus (MRSA) is an established nosocomial pathogen, but has
recently begun to appear in the community. The clones in the community may not have originated in the
hospital setting, and are referred to as community-acquired MRSA (CA-MRSA). Resistance to
methicillin is mediated by the gene mecA, which is carried by the mobile genetic element staphylococcal
cassette chromosome mec (SCCmec). SCCmec typing (I–IV) of all clinical isolates of MRSA (n = 92) from
1987 to 2004 in O¨rebro County, Sweden, was performed by real-time LightCycler PCR to detect the
essential genetic components mecA, mecR1, IS1272, ccrA and ccrB. Forty-one isolates harboured type IV
SCCmec, of which ten could be classiﬁed further as subtype IVa, and 27 as subtype IVc. No isolates
belonged to subtype IVb, but four isolates could not be subtyped, and may be examples of novel type IV
SCCmec subtypes. Thirty-ﬁve MRSA isolates, assigned to six different pulsotypes by pulsed-ﬁeld gel
electrophoresis, did not belong to SCCmec types I–IV. The Panton-Valentine leukocidin (PVL) genes
were identiﬁed in two of these pulsotypes. Only SCCmec type IV has been associated previously with
the PVL toxin, but the results suggest that new PVL-positive clones with novel SCCmec types may be
arising and disseminating in the community.
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INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA)
was ﬁrst described in 1961 [1] and such bacteria
have emerged subsequently as a major world-
wide nosocomial problem. Strains of epidemic
MRSA (EMRSA) are well-adapted to survive,
spread and colonise humans in a hospital envi-
ronment [2], as exempliﬁed in the UK by the
EMRSA-15 and EMRSA-16 clones which predom-
inate in UK hospitals and account for >95% of
MRSA bacteraemias [3]. Investigators in several
countries have reported that the epidemiology
of MRSA is changing, and there is growing con-
cern regarding the MRSA strains that are now
appearing in the community [4–8]. Community-
acquired MRSA (CA-MRSA) refers to strains
isolated from individuals who have not recently
been in contact with a hospital or long-term care
facility, received antibiotic treatment, nor have
other risk-factors for MRSA. CA-MRSA causes
predominantly skin and soft tissue infections,
and has been identiﬁed as a signiﬁcant problem
among Australian aborigines [9], intravenous
drug users [10,11], prison inmates [12,13] and
other categories of individuals [14–16]. The
reports of four paediatric deaths caused by a
CA-MRSA clone in the USA [5] have attracted the
attention of physicians worldwide, and have led
to increased interest in ﬁnding the origin of
CA-MRSA.
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Methicillin-resistance in S. aureus is character-
ised by the expression of an altered penicillin-
binding protein, PBP2a (or PBP2¢), with decreased
afﬁnity for all b-lactam antibiotics, which thereby
allows continuous cell-wall assembly. PBP2a is
encoded by mecA and its regulatory genes, which
are located in a mobile genetic element termed
staphylococcal cassette chromosome mec
(SCCmec), and incorporated in the chromosome
of S. aureus at a site-speciﬁc location near the
origin of replication [17,18]. Cloning and sequen-
cing of SCCmec from various MRSA strains has
revealed ﬁve different allotypes that are designa-
ted SCCmec types I–V [17–20]. Each of these
SCCmec elements carries a characteristic combi-
nation of two essential genetic components,
known as the mec gene complex and the cassette
chromosome recombinase (ccr) gene complex. The
mec gene complex consists of the insertion
sequence IS431, together with mecA and its
regulatory genes mecI and mecR1, which can be
either intact or mutated. Three different mec gene
complexes (classes A, B and C2) have been
described in SCCmec types in S. aureus. The ccr
gene complex comprises the genes ccrA and ccrB,
which code for two recombinases that are
required for site-speciﬁc integration and excision
of SCCmec. There are at least three allotypes of
ccrA and ccrB (types 1–3) in SCCmec, but only
type 2 has been shown to be functionally intact
[17,21,22]. Most recently, a novel ccrC gene com-
plex (or type 5 ccr), responsible for recombination
events of type V SCCmec, was identiﬁed in MRSA
strain WIS [20]. The SCCmec allotypes are classi-
ﬁed as I–V, depending on the combination of the
mec gene complex and the ccr gene complex that is
present. Further classiﬁcation of the type IV
SCCmec is based on differences in the remaining
areas of SCCmec, which are referred to as junk-
yard (J) regions. Previously, all isolates collected
from various countries have been found to carry
subtype IVa or IVb [7], but Ito et al. [21] recently
identiﬁed a novel type IVc SCCmec in an isolate
(81 ⁄ 108) from an outpatient in Japan.
It is a matter of debate as to whether the newly
emerging CA-MRSA strains were derived from
existing hospital-acquired strains (HA-MRSA)
and were transmitted to the community, or
whether they evolved independently [4,14,23,24].
It has been proposed that all MRSA are descend-
ants of a single common ancestor which has
spread worldwide [25], while an alternative sug-
gestion is that SCCmec has been acquired hori-
zontally on several occasions from other
staphylococcal species in the non-hospital envi-
ronment [2,26–28]. Several molecular typing tech-
niques have been used to study large collections
of MRSA isolates from different geographical
areas, and have revealed relatively few pandemic
clones [2,23,26,27,29,30]. In contrast, CA-MRSA
strains have been found to comprise at least ten
clonal complexes, which indicates that these
bacteria originated from S. aureus clones with a
greater genetic diversity than HA-MRSA strains
[2,26]. SCCmec types I–IV all occur among health-
care-associated isolates, whereas the type IV
SCCmec is the predominant element in CA-MRSA
[4,18]. There is an obvious association between
the ﬁve major clonal complexes and the hospital-
acquired SCCmec types I, II and III. However, the
type IV SCCmec is found in S. aureus isolates with
several different genetic backgrounds, is smaller
than the other SCCmec types, and generally does
not contain any additional resistance genes,
which may facilitate its mobility. Type IV SCCmec
contains functional recombinases, and it has been
found in many clones, which further suggests that
this element is more mobile than the other
SCCmec types [4,18,29,31]. It is possible that
strains with different types of SCCmec have
evolved from genetic backgrounds with addi-
tional virulence traits and the ability to dissem-
inate [29,32].
The aim of this study was to investigate the
distribution of SCCmec types I–IV among MRSA
isolates from O¨rebro County, Sweden, with spe-
cial focus on the characterisation of CA-MRSA
isolates by LightCycler PCR analysis of the
various types of ccr and mec gene complexes.
MATERIALS AND METHODS
Bacterial isolates
All clinical isolates of MRSA (n = 92) identiﬁed between 1987
and 2004 in O¨rebro County (population c.280 000) were
analysed. In Sweden, contact tracing is conducted according
to the Communicable Diseases Act, and essential epidemio-
logical information has been collected and available in a
county database since 2000. Isolates were stored at )70C at the
Department of Clinical Microbiology at O¨rebro University
Hospital.
Community-acquired infection was recorded following
identiﬁcation of MRSA in an outpatient setting, or if a patient
was positive for MRSA within 48 h of admission to a hospital,
provided that the patient had no medical history of MRSA
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infection or colonisation, no hospitalisation, admission to a
nursing home, dialysis or surgery during the previous year,
and no permanent indwelling catheters or medical devices that
penetrated the skin. Using these criteria, 36 (39%) of 92 MRSA
isolates were categorised as CA-MRSA, 46 (50%) as HA-
MRSA, and ten (11%) could not be categorised because of lack
of epidemiological information. Isolates were derived from
skin (n = 56), nares (n = 14) and other sites (n = 3), or
information concerning the site was not available (n = 19).
S. aureus was identiﬁed by conventional microbiological
methods, including DNase and coagulase tests. Antibiotic
susceptibility testing was performed by disk diffusion and
Etests (AB Biodisk, Solna, Sweden), as recommended by the
Swedish Reference Group for Antibiotics (SRGA) and the
SRGA Subcommittee on Methodology (SRGA-M) (http://
www.srga.org). The following antibiotics were tested:
oxacillin ⁄ cefoxitin, fusidic acid, clindamycin, ciproﬂoxacin,
erythromycin, gentamicin, rifampicin and vancomycin. Chlo-
ramphenicol, trimethoprim-sulphamethoxazole andmupirocin
were also tested with selected isolates. Resistance to oxacillin
was measured by Etest, with resistance deﬁned as an MIC of
>1.0 mg ⁄L according to the SRGA. Isolates were veriﬁed as
MRSA by detecting the nuc and mecA genes (see below).
Six international MRSA strains characterised previously
were used as controls for SCCmec typing: reference strains 8 ⁄ 6-
3P (JCSC1978), CA05 (JCSC1968), MR108 and JCSC4469 were
kindly provided by T. Ito and K. Hiramatsu (Department of
Bacteriology, Juntendo University, Tokyo, Japan), and strains
M307 (E-MRSA3) and 98 ⁄ 514 (Helsinki VII, E20), were
obtained from the HARMONY collection [33]. Strain RS12
(ATCC 29213), which lacks mecA, was used as a negative
control.
DNA isolation
All isolates were cultured on blood agar and incubated
overnight at 37C. DNA was isolated from the reference
strains with the Dynabeads DNA DIRECT System I kit (Dynal
Biotech, Oslo, Norway) for higher purity and longer stability.
Genomic DNA was extracted from clinical isolates by dena-
turing a few colonies suspended in sterile water at 98C for
15 min and then centrifuging at 13 000 g for 30 s. The
supernatant was used as template for ampliﬁcation in a real-
time PCR in the LightCycler System (Roche Diagnostics,
Mannheim, Germany) and speciﬁc binding of SYBR Green I
ﬂuorescent dye to the resulting double-stranded DNA.
Detection of nuc and mecA
The isolates were veriﬁed as MRSA by using a multiplex PCR
adapted for the LightCycler and SYBR Green I to detect the nuc
(forward primer, 5¢-GCGATTGATGGTGATACGGTT-3¢;
reverse primer, 5¢-AGCCAAGCCTTGACGAACTAAAGC-3¢)
and mecA (forward primer, 5¢-GCAATCGCTAAAGAAC-
TAAG-3¢; reverse primer, 5¢-GGGACCAACATAACCTAAT-
A-3¢) genes [34]. Samples were preincubated for 10 min at 95C
and then subjected to 35 cycles of ampliﬁcation comprising
95C for 10 s, 55C for 5 s and 72C for 8 s. The melting
programme comprised one cycle of 95C for 0 s (hold time)
and 58C for 1 min, followed by an increase in temperature at
a transition rate of 0.1C ⁄ s to 95C while continuously
monitoring ﬂuorescence.
Determination of SCCmec type
The ccr gene complex and the mec gene complex were detected
in separate PCRs. The primers used to identify SCCmec types
I–IV (Table 1) were as reported previously [7,17,35], with the
exception of IVc1, IVc2, and clB. The class A mec gene complex
was identiﬁed by use of the mcR2 and mcR5 [7] primers, which
are speciﬁc for the penicillin-binding domain of mecR1.
Primers clB (this study) and IS4 [35] correspond to the
nucleotide sequence of IS1272, which is a component of the
class B mec complex. The ccr type was determined by combi-
ning the common primer for ccrB (b2) [17] with speciﬁc
primers for ccrA1 (a2), ccrA2 (a3) and ccrA3 (a4) [17]. All
Table 1. Sequences of primers used
to detect the components of SCCmec
Primer Nucleotide sequence 5¢-3¢ Position (bp) Accession numbera Reference
ccr gene complexb
b2 ATTGCCTTGATAATAGCCITCT 25539–25522 (ccr 1) AB033763 [17]
11738–11720 (ccr 2) AB063172
7276–7258 (ccr 3) AB037671
a2 AACCTATATCATCAATCAGTACGT 24845–24868 (ccrA1) AB033763 [17]
a3 TAAAGGCATCAATGCACAAACACT 10802–10825 (ccrA2) AB063172 [17]
a4 AGCTCAAAAGCAAGCAATAGAAT 5486–5508 (ccrA3) AB037671 [17]
mec gene complex
class A
mcR2 CGCTCAGAAATTTGTTGTGC 22758–22777 AB037671 [7]
mcR5 CAGGGAATGAAAATTATTGGA 23076–23056 [7]
class B
IS4 ACAATCTGTATTCTCAGGTCGT 14846–14867 AB063172 [35]
clB CGATTGGCATTTGCTTCAAT 15088–15069 This study
SCCmec
subtype IVa
4a1 TTTGAATGCCCTCCATGAATAAAAT 4726–4750 AB063172 [7]
4a2 AGAAAAGATAGAAGTTCGAAAGA 5183–5161 [7]
subtype IVb
4b1 AGTACATTTTATCTTTGCGTA 2266–2286 AB063173 [7]
4b2 AGTCATCTTCAATATCGAGAAAGTA 3259–3235 [7]
subtype IVc
IVc1 CCAGAGAAATGTGGTGTTTT 8923–8942 AB096217 This study
IVc2 GCCCTACATGAATCATCAAA 9128–9109 This study
aThe accession number is available in the GenBankTM database (http://www.ncbi.nlm.nih.gov). bThe type of ccr
gene complex is determined by using primer b2 (the common primer for three types of ccrB) and one of the primers
a2, a3, or a4 (to reﬂect the three allotypes of ccrA).
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isolates were analysed with the primers for each gene complex
in separate reactions. Further subtyping was performed on the
isolates that were classiﬁed as SCCmec type IV by examining
nucleotide differences in the junkyard region (J1). Primers
used to identify the SCCmec subtypes were as follows: 4a1 and
4a2 [7] for subtype IVa; 4b1 and 4b2 [7] for subtype IVb; and
IVc1 and IVc2 (this study) for subtype IVc. All primers were
synthesised by Scandinavian Gene Synthesis (Ko¨ping,
Sweden).
All PCR reagents, except primers and template DNA, were
provided in the LightCycler FastStart DNA Master SYBR
Green I kit (Roche). Each reaction contained 2 lL of SYBR
Green I and 2 lL of DNA template (1–40 ng) and was
performed in a LightCycler glass capillary in a total volume
of 20 lL. Cycling conditions were optimised for each Light-
Cycler PCR, including MgCl2 and primer concentrations,
annealing temperatures and extension times. The ﬁnal optim-
ised conditions are summarised in Table 2.
Ampliﬁcation products were characterised by melting
curve analysis to increase the sensitivity and speciﬁcity of
SYBR Green I detection. The melting programme comprised
one cycle of 95C for 0 s (hold time) and 65C for 15 s, followed
by an increase in temperature at a transition rate of 0.1C ⁄ s to
95C, while continuously monitoring ﬂuorescence. The sam-
ples were then cooled to 40C over a period of 30 s. Melting
peaks were derived from the initial melting curves (ﬂuores-
cence (F1) vs. temperature (T)) by plotting (– dF1 ⁄ dT vs. T). The
speciﬁc melting temperatures (Tm) obtained from all runs of
the isolates analysed (n = 92) and reference strains (n = 6)
were used to calculate the mean Tm for each gene (Table 3).
Initial veriﬁcation
The identities of the PCR products were conﬁrmed initially
by gel electrophoresis and sequencing of the ampliﬁcation
products from the reference strains. Before sequencing, the
products were puriﬁed with a High Pure PCR Puriﬁcation
Kit (Roche). Sequencing was performed with an ABI PRISM
BigDye Terminator v.3.0 Ready Reaction Cycle Sequencing
Kit (Applied Biosystems, Stockholm, Sweden) and a Gene-
Amp PCR System 2700 (Applied Biosystems), using the
same primers as for the LightCycler PCRs. Both strands
were sequenced. Reaction products were puriﬁed using a
Qiagen DyeEx 2.0 Spin kit (VWR International, Stockholm,
Sweden) and then separated on an ABI PRISM 310 Genetic
Analyzer (Applied Biosystems). The nucleotide sequences
were analysed using ABI PRISM AutoAssembler DNA
Sequence Assembly 1.4.0 software, and were then compared
with sequence databases at the National Center for Biotech-
nology Information (NCBI; Bethesda, MD, USA) with the
basic local alignment search tool BLAST (http://
www.ncbi.nlm.nih.gov). In addition, the presence of sub-
type IVc in a clinical isolate was veriﬁed initially by
sequencing the product ampliﬁed when using the above
primers and comparing the sequenced region with the
BLAST database at NCBI.
Detection of lukS-PV and lukF-PV
The LightCycler and SYBR Green I dye were used to detect
PVL genes by PCR as described previously [36].
Pulsed-ﬁeld gel electrophoresis
The 92 MRSA isolates were characterised by pulsed-ﬁeld gel
electrophoresis (PFGE) of chromosomal SmaI digests, prepared
with the GenePath Group 1 Reagent Kit (Bio-Rad Laboratories,
Hercules, CA, USA). PFGE patterns were obtained with a
contour-clamped homogeneous electric ﬁeld apparatus (Gene-
Path System; Bio-Rad) run for 20 h with agarose 1% w ⁄v gels
in 0.5 · Tris-borate buffer at 6 V ⁄ cm with a switching time of
5.3–34.9 s. Differences in band patterns were analysed with
Molecular Analyst Fingerprinting software v.1.6 (Bio-Rad)
using the Dice coefﬁcient and unweighted pair grouping by
Table 2. LightCycler parameters





MgCl2 (mM) Primers (lM) Denat Ann Ext
ccr 1 3 a2 (0.5) b2 (0.5) 30 95 C, 10 s 59 C, 5 s 72 C, 28 s
ccr 2 3 a3 (0.5) b2 (0.7) 30 95 C, 10 s 55 C, 5 s 72 C, 38 s
ccr 3 4 a4 (0.3) b2 (0.7) 35 95 C, 10 s 59 C, 5 s 72 C, 70 s
Class A mec complex 3 mcR2 (0.3) mcR5 (0.3) 25 95 C, 10 s 61 C, 5 s 72 C, 13 s
Class B mec complex 5 IS4 (0.3) clB (0.5) 30 95 C, 10 s 56 C, 5 s 72 C, 10 s
Subtype IV a 4 4a1 (0.5) 4a2 (0.3) 30 95 C, 10 s 51 C, 5 s 72 C, 18 s
Subtype IV b 4 4b1 (0.3) 4b2 (0.5) 30 95 C, 10 s 51 C, 5 s 72 C, 40 s
Subtype IV c 3 IVc1 (0.7) IVc2 (0.3) 25 95 C, 10 s 50 C, 5 s 72 C, 9 s
aTyping of SCCmec was performed in eight separate reactions. The PCR programme starts with a preincubation for
10 min at 95 C to activate the FastStart polymerase, followed by ampliﬁcation under different conditions for each
gene. The ﬂuorescence was measured at the end of each extension step for real-time visualisation.
Table 3. Melting temperatures (mean Tm) for positive
clinical isolates (n = 92) and reference strains (n = 6)
Assay Sample
No. positive ⁄
No. tested Mean Tm C (SD)
ccr 1 Reference 5 ⁄ 5 81.3 (0.3)
Clinical isolates 5 ⁄ 92 80.9 (0.1)
ccr 2 Reference 10 ⁄ 10 81.2 (0.7)
Clinical isolates 44 ⁄ 92 81.5 (0.4)
ccr 3 Reference 7 ⁄ 7 82.2 (0.3)
Clinical isolates 8 ⁄ 92 81.9 (0.2)
Class A mec
complex
Reference 6 ⁄ 6 75.9 (0.5) and 80.0 (0.5)a
Clinical isolates 11 ⁄ 92 75.7 (0.4) and 79.9 (0.2)a
Class B mec
complex
Reference 4 ⁄ 4 77.3 (0.1)
Clinical isolates 46 ⁄ 92 77.1 (0.2)
Subtype IVa Reference 10 ⁄ 10 77.9 (0.2)
Clinical isolates 10 ⁄ 41b 77.9 (0.2)
Subtype IVb Reference 10 ⁄ 10 78.5 (0.4)
Clinical isolates 0 ⁄ 41b No positive isolates
Subtype IVc Reference 4 ⁄ 4 74.5 (0.2)
Clinical isolates 27 ⁄ 41b 74.1 (0.2)
aAn additional peak was seen in all runs. bOnly isolates with a type IV SCCmec
(n = 41) were differentiated further.
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mathematical averaging (UPGMA), with a 1% band tolerance
and 0.5% optimisation, followed by ﬁnal visual examination
and interpretation as recommended by Tenover et al. [37].
RESULTS
Table 4 summarises the results of the SCCmec
typing. This analysis indicated that among the 92
MRSA isolates studied, ﬁve (5.4%) had SCCmec
type I, three (3.3%) had type II, eight (8.7%) had
type III, and 41 (44.6%) had type IV. The 41
isolates with type IV SCCmec could be further
differentiated into ten (24.4%) isolates with sub-
type IVa, and 27 (65.9%) isolates with sub-
type IVc. No isolates with subtype IVb were
detected, and the remaining four (9.8%) isolates
had an unknown subtype of type IV SCCmec.
Thirty-ﬁve (38.0%) of the 92 isolates were not
typable with the primers used in this study for
PCR ampliﬁcation of the ccr or mec gene com-
plexes.
Isolates with type IV SCCmec usually had
lower oxacillin MICs (85% had an MIC <
256 mg ⁄L; median 8, range 1.5 - >256) and were
rarely resistant to any of the other antibiotics
tested. However, most (20 ⁄ 27) of the isolates with
type IVc SCCmec were resistant or showed de-
creased sensitivity to fusidic acid, and sometimes
also to ciproﬂoxacin and gentamicin. Most (27 ⁄ 35)
of the isolates with unknown SCCmec types were
resistant to gentamicin, and one isolate was
resistant to rifampicin and another to trimetho-
prim-sulphamethoxazole. Moreover, ﬁve of the 35
untypable isolates had higher oxacillin MICs
(>256 mg ⁄L), while the other untypable isolates
were less resistant (MICs of 1.5–4 mg ⁄L),
although one isolate had an oxacillin MIC of
48 mg ⁄L.
Most (66%) of the 41 isolates with type IV
SCCmecwere CA-MRSA, although this group also
included eight HA-MRSA isolates; in comparison,
only two of 27 isolates with SCCmec subtype IVc
were HA-MRSA. Sixteen (40%) of the 41 type IV
SCCmec isolates had a known origin outside
Sweden (Somalia, Yugoslavia, Lebanon or Spain).
Of the 35 isolates with untypable SCCmec, 25
(71.4%) were HA-MRSA, including 20 isolates
from a local outbreak in a neonatal intensive care
unit (ICU) and ﬁve other isolates that were linked
indirectly to the same outbreak. Only ﬁve (14.3%)
of the 35 SCCmec-untypable isolates had a known
origin outside Sweden (China and Kazakhstan),
while the remaining isolates of unknown SCCmec
type comprised sporadic CA-MRSA isolates.
PFGE analysis showed that the ten isolates with
subtype IVa SCCmec could be divided into four
pulsotypes (Fig. 1), and that pulsotype D inclu-
ded six of these ten isolates. The 27 isolates with
SCCmec subtype IVc clustered into ﬁve pulso-
types (Fig. 1), and most (20 ⁄ 27) of these isolates
were indistinguishable or closely related (pulso-
type F). The four isolates with a type IV SCCmec
that could not be further subtyped belonged to
four different pulsotypes (Fig. 1). The PFGE
results also showed that the 35 isolates with a
non-typable SCCmec were grouped into six puls-
otypes (Fig. 1), and that most (26 ⁄ 35; pulsotype E)
were indistinguishable or closely related; all
except one of these were linked directly or
indirectly to an MRSA outbreak at a neonatal ICU.
None of the isolates with type I, II or III SCCmec
carried the genes for PVL toxin. However, 22
(81.5%) of 27 isolates with type IVc SCCmec
carried these genes; no other isolates with type IV
SCCmec were positive. Six of the 35 isolates that
were SCCmec untypable were positive for the PVL
toxin genes, with four of these isolates originating
from Kazakhstan. Two additional isolates also
carried the PVL genes, but there was no obvious
Table 4. Types of staphylococcal
cassette chromosome mec (SCCmec)
found in MRSA isolates collected in
O¨rebro County, Sweden No. of isolates








PVL+1 2 3 A B a b c d
5 I + – – – + 0
3 II – + – + – 0
8 III – – + + – 0
41 IV – + – – + 22 (54%)
10 ⁄ 41 IVa + – – – 0
0 ⁄ 41 IVb – + – – 0
27 ⁄ 41 IVc – – + – 22 (81%)
4 ⁄ 41 IV unknown – – – – 0
35 unknown – – – – – 6
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Si  02T659 NT - CA  
Si 02T773 IVc + CA  
Si  01T796 NT  - Un  
Si  99T047 IV  - CA  
A 01T902 NT + CA  
A 02T565 NT + CA  
Si 01T029 IVa - HA  
B 99T554 IVa - CA  
B 00T278 IVa - CA  
C 02T284 NT + CA  
C 02T306 NT + CA  
C 02T307 NT + CA  
C 02T349 NT + CA   
Si 98T019 IV   - HA  
D 98P013 IVa - HA  
D 98P020 IVa - HA  
D1 95T041 IVa - Un  
D2 04T206 IVa - CA  
D2 04T201 IVa - CA  
D3 00T648 IVa - HA  
D4 01T384 IV - HA  
D5 96T105 IVc - HA  
E   99T318 NT   - HA  
E   99T386 NT - HA  
E   98P079 NT - HA  
E 98P033 NT - HA  
E   99P034 NT - HA  
E   98P071 NT   - HA  
E1 98P036 NT  - HA  
E1 98P047 NT  - HA  
E1 98P046 NT  - HA  
E1 98P038 NT - HA  
E1 98P048 NT  - HA  
E1 99T361 NT  - HA  
E1 98P075 NT  - HA  
E1 98P068 NT  - HA  
E1 99T675 NT  - HA  
E1 99T650 NT  - HA  
E1 99T655 NT  - HA  
E1 99T651 NT  - HA  
E2 98B269 NT  - HA  
E2 98P055 NT  - HA  
E2 98P030 NT  - HA  
E2 98P040 NT  - HA  
E2 98T081 NT  - HA  
E2 98B249 NT  - HA  
E3 99T376 NT  - CA  
E4 99T299 NT  - HA  
F 03T010 IVc + Un  
F 03T498 IVc + CA  
F 03T509 IVc + CA  
F 03T704 IVc + CA  
F   03T720 IVc + CA  
F   04T181 IVc + CA  
F   02T579 IVc + Un  
F   02T621 IVc + CA  
F 02T635 IVc + CA  
F1 00T005 IVc + CA  
F1 00T006 IVc + CA  
F2 04T131 IVc + CA  
F2 03T510 IVc + CA  
F2 04T109 IVc + CA  
F2 02T150 IVc + CA  
F3 01T035 IVc + CA  
F3 01T947 IVc + CA  
F3 01T948 IVc + CA  
F3 01T936 IVc + CA  
F4 04T001 IVc + CA  
Si  02T884 IVc + CA  
Si  95T049 IV   - CA  
G  01T044 IVc  - CA  
G  99T240 IVc  - CA  
G1 03T137 IVc - CA  
G2 99T576 IVc - HA  
Si  02P747 NT  - CA  
Si  03T812 IVa - Un  
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epidemiological link between the two patients
who were infected with these two isolates.
DISCUSSION
Most (45%) of the 92 MRSA isolates from O¨rebro
County in this study contained type IV SCCmec,
but only ten (24%) had SCCmec subtype IVa. In
contrast to those ﬁndings, Okuma et al. [7] ana-
lysed 32 type IV SCCmec isolates from the USA
and Australia, and found that 31 were sub-
type IVa and one was subtype IVb. Also, 27 of
the 41 type IV SCCmec isolates in the present
study were subtype IVc, a variant that was ﬁrst
identiﬁed in Japan [21] and was described
recently as hospital-acquired in France [38]. Fur-
thermore, the 41 type IV SCCmec isolates con-
tained no isolates with subtype b, although four
of the isolates could not be differentiated further
and may therefore represent a novel subtype(s).
Thirty-ﬁve of the 92 MRSA isolates studied did
not carry any of the genetic structures that are
known to exist in SCCmec types I–IV. Oliveira
et al. [30] have reported an altered type IV
SCCmec with a new type of ccr gene complex
and a class B mec complex, but the untypable
isolates investigated in the present study could
not have belonged to that clone, since they did not
contain a class B mec complex.
It has been reported that SCCmec subtypes IVa
and IVb do not carry additional genes for anti-
biotic resistance [7,18] whereas 20 (74%) of the
isolates in the present study with subtype IVc
were resistant to fusidic acid. Furthermore, strain
81 ⁄ 108 (referred to as MR108 in the present study)
was the ﬁrst isolate observed to carry SCCmec
subtype IVc, and this element has been found to
contain Tn4001 and the aacA and aphD genes
encoding resistance to aminoglycosides [21,39].
Only one SCCmec subtype IVc isolate from O¨re-
bro County was resistant to gentamicin. Type IV
SCCmec was ﬁrst recognised in 2002 [18], but has
been found subsequently in S. aureus isolates
from the early 1980s [40], and has been prevalent
in Staphylococcus epidermidis isolates since the
1970s [40]. Therefore, it is plausible that type IV
SCCmec has subsequently acquired additional
genes following exposure to antibiotic selection
pressures in hospitals. By adapting to a hospital
environment and acquiring additional resistance
genes, the type IV SCCmec may become so large
that it loses its ability to transfer horizontally.
Isolates (n = 35) that were SCCmec untypable,
including the 25 isolates that were directly or
indirectly linked to an MRSA outbreak at a
neonatal ICU, generally had lower oxacillin MICs,
with the exception of four isolates originating
from Kazakhstan and one isolate that originated
from China. All outbreak isolates and three
additional isolates were resistant to gentamicin.
In contrast to the ﬁnding of SCCmec sub-
type IVc in HA-MRSA in France [38], most
(78%) of the isolates with that subtype in O¨rebro
County were CA-MRSA. In addition, most
isolates with unknown types of SCCmec were
CA-MRSA, with the exception of the isolates
associated with the outbreak in the neonatal ICU.
New variants of SCCmec have been described in
methicillin-resistant coagulase-negative staphylo-
cocci (CoNS) in Norway [41], but only one MRSA
isolate in that study was found to have an
untypable SCCmec. It is tempting to suggest that
the untypable strains in O¨rebro County carried
novel types of SCCmec. A new SCCmec type,
designated type V, consisting of a ccrC recomb-
inase complex and the class C2 mec gene complex,
has been described recently by Ito et al. [20].
It is assumed that SCCmec originated in CoNS
[28,35], and three additional mec gene complexes
(C1, C2, and D) have been identiﬁed in CoNS,
while the class C2 mec complex occurs widely in
strains of Staphylococcus haemolyticus [35]. In the
present study, 20 of the HA-MRSA isolates with
unknown SCCmec were involved in the ICU
outbreak in 1998; it is notable that an endemic
situation existed for several years with a speciﬁc
methicillin-resistant genotype of S. haemolyticus in
the neonatal ward, and that the MRSA outbreak
took place during that period [42].
PFGE analysis showed that the ten isolates with
SCCmec subtype IVa belonged to four different
pulsotypes, one of which contained six of the
isolates. SCCmec subtype IVc isolates clustered
into ﬁve pulsotypes, of which two predominated.
Fig. 1. Pulsed-ﬁeld gel electrophoresis patterns of SmaI-
digested total chromosomal DNA from MRSA isolates
with type IV SCCmec and nontypable (NT) isolates for
SCCmec types I–IV. Clone designation, SCCmec-type and
the presence (+) or absence (–) of the genes for Panton-
Valentine leukocidin is indicated to the right of the
dendrogram. The origin of isolates is indicated by CA
(community-acquired), HA (hospital-acquired) or Un
(unknown).
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Interestingly, no epidemiological or geographical
correlation was found between isolates that
belonged to the same pulsotype. The four isolates
with an unknown subtype IV SCCmec were all
unrelated and displayed no epidemiological
linkage. PFGE analysis showed that there was
substantial genetic diversity between isolates with
type IV SCCmec, perhaps indicating that type IV
SCCmec improves the capacity for transfer
between different genetic clones of S. aureus.
PFGE differentiated the group of 35 isolates with
untypable SCCmec into six pulsotypes. Several
CA-MRSA strains appear to be virulent [5] and
possess multiple toxin genes that are not present
in the genomes of HA-MRSA. This further sug-
gests that CA-MRSA were generated independ-
ently of HA-MRSA by insertion of SCCmec into
the genomes of virulent S. aureus strains, resulting
in highly pathogenic CA-MRSA clones. PVL is
expressed by c.2% of S. aureus isolates and is
encoded by the lukS-PV and lukF-PV genes, which
are carried on a bacteriophage [43]. Production of
PVL has been described in CA-MRSA, albeit only
in strains with a type IV SCCmec [7,44], and
although lukS-PV and lukF-PV are not part of
SCCmec, the presence of PVL among isolates with
type IV SCCmec may facilitate spreading and
colonisation by causing primary skin infections.
It has been reported that PVL-producing strains
cause lethal necrotising pneumonia in otherwise
healthy young patients with no established risk
factors for MRSA [38,45]. Furthermore, Liassine
et al. [44] have described CA-MRSA strains in
Europe which, in addition to PVL, express
enterotoxins and exfoliative toxins.
The present analysis of the presence of the lukF-
PV and lukS-PV genes in the MRSA isolates
yielded three notable ﬁndings. First, ﬁve
CA-MRSA clones in O¨rebro County carried the
PVL genes, which can be compared with a study
showing that CA-MRSA infections in France are
caused by a single clone in which all isolates
express PVL [38]. Second, most (22 ⁄ 28) isolates
carrying the PVL genes in O¨rebro County carried
SCCmec subtype IVc, and these isolates could be
differentiated into three clusters by PFGE. No
other subtype of SCCmec type IV carrying the
PVL genes was identiﬁed. Overall, 70% of
CA-MRSA and 66% of isolates with type IV
SCCmec in this area carried the PVL genes. Third,
some isolates in O¨rebro County with unknown
types of SCCmec were positive for PVL. These
isolates belonged to two clusters (A and C), with
one cluster (A) exhibiting higher levels of oxacil-
lin resistance (MIC >256 mg ⁄L), while the other
(C) was less resistant to oxacillin but was resistant
to gentamicin. Thus far, only type IV SCCmec (i.e.,
not types I, II or III) has been associated with the
PVL toxin [7,44], but it is possible that new MRSA
clones are evolving and disseminating in the
community, and that such clones may carry a
novel SCCmec that offers a selective advantage for
the colonisation of humans in the absence of
antibiotic selection, e.g., by encoding the expres-
sion of toxins. None of the HA-MRSA isolates
studied contained the PVL genes.
In conclusion, the epidemiology of MRSA in
Sweden is changing, with an increasing propor-
tion of CA-MRSA. The type IVc SCCmec is the
predominant element among CA-MRSA, and
many isolates may also carry novel types of
SCCmec. The presence of PVL toxin may facilitate
dissemination in a non-hospital environment. The
origin of SCCmec has not been determined, but
these elements are found commonly in CoNS,
which may be a possible source.
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